Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of February 2026, specifically detailing share repurchases executed on February 20, 2026. The transaction was conducted through BNP Paribas SA as part of GSK's existing buyback programme under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. It does not contain revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (Feb 20, 2026): 467,000 ordinary shares.
- Lowest Price Paid: 2,200.00 GBp.
- Highest Price Paid: 2,242.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,223.53 GBp.
- Total Shares Purchased Since Feb 17, 2026: 1,767,000 ordinary shares.
- Treasury Shares Held: 241,658,094 ordinary shares.
- Shares in Issue (excluding Treasury): 4,074,494,332 ordinary shares.
- Treasury Voting Rights Percentage: 5.93%.
Material Changes
The filing details a reduction in the number of shares in issue and an increase in treasury shares held by the company. Since the commencement of the current non-discretionary agreement on February 17, 2026, the company has repurchased 1,767,000 shares. The specific transaction on February 20, 2026, added 467,000 shares to the treasury. The filing does not provide comparative financial data against prior periods as it is a transaction report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and GSK's Q4 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares in issue (4,074,494,332) for accurate calculation of ownership percentages under Disclosure Guidance and Transparency Rules.
- Confirm the current percentage of voting rights held in treasury (5.93%) to assess potential dilution or concentration of voting power.
- Review the non-discretionary agreement terms announced on February 17, 2026, to understand the remaining capacity or duration of the buyback programme.
- Check the "Risk Factors" in the 2024 Form 20-F and Q4 2025 results for context on the company's broader financial health, as this filing does not provide operational metrics.